• OPEN AN ACCOUNT
Indian Indices
Nifty
22,442.70 -33.15
(-0.15%)
Sensex
73,895.54 17.39
( 0.02%)
Bank Nifty
48,895.30 -28.25
( -0.06%)
Nifty IT
33,217.15 308.75
( 0.94%)
Global Indices
Nasdaq
16,156.33 315.37
(1.99%)
Dow Jones
38,675.68 450.02
(1.18%)
Hang Seng
18,578.30 102.38
(0.55%)
Nikkei 225
38,236.07 -37.98
(-0.10%)
Forex
USD-INR
83.43 -0.03
(-0.04%)
EUR-INR
89.37 0.26
(0.29%)
GBP-INR
104.48 0.21
(0.20%)
JPY-INR
0.54 0.01
(1.69%)

EQUITY - MARKET SCREENER

Nirbhay Colours India Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
526349
INE218T01010
6.5653731
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
50
0.34
EPS(TTM)
Face Value()
Div & Yield %
0.02
10
0
 

Dr Reddys Laboratories Ltd
Nestle India and Dr Reddy's to form JV focused on nutritional health solutions
Apr 25,2024

Nestlé India and Dr. Reddy's Laboratories announced that they have entered into a definitive agreement to form a joint venture to bring innovative nutraceutical brands to consumers in India and other agreed territories.

The partnership will bring together the well-known global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestlé Health Science (NHSc) with the strong and established commercial strengths of Dr. Reddy's in India.

The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios in categories such as metabolic, hospital nutrition, general wellness , women's health and child nutrition for consumers across India. The JV Company will be headquartered in Hyderabad. The JV Company will leverage the capabilities as well as services of the Nestlé Group and Dr. Reddy's.

Select brands will be licensed by the JV Partners to the JV company. The Nestlé Group will license brands such as Nature's Bounty, Osteo Bi-Flex, Ester-C, Resource High Protein, Optifast, Resource Diabetic, Peptamen, Resource Renal and Resource Dialysis. Dr. Reddy's will license brands such as Rebalanz, Celevida, Antoxid, Kidrich-D3, Becozinc in the nutrition, and OTC segments. The JV Company is expected to become operational in Q2 of FY'25.